Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15692748 | 0.90 | PEPD (0.40) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL1979535 | 0.88 | CYP3A4 (0.37) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL12772907 | 0.87 | CYP3A4 (0.36) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL1981741 | 0.87 | PEPD (0.42) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL12773346 | 0.86 | PEPD (0.45) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL19792172 | 0.86 | PEPD (0.45) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL15586366 | 0.83 | MMP2 (0.38) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL206302 | 0.83 | MMP2 (0.38) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL205475 | 0.83 | MMP2 (0.38) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL19593019 | 0.83 | MMP2 (0.38) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9416139-B2 | Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-9416139-B2 | Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-9303061-B2 | Spiro compounds as Hepatitis C virus inhibitors | Sunshine Luke Pharma Co., Ltd. (CN) | 2016-04-05 | — | — | US | disclosed |
| US-9303061-B2 | Spiro compounds as Hepatitis C virus inhibitors | Sunshine Luke Pharma Co., Ltd. (CN) | 2016-04-05 | — | — | US | disclosed |
| EP-2730572-B1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2015-09-16 | — | — | EP | disclosed |
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-05-29 | — | — | US | disclosed |
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-05-29 | — | — | US | disclosed |
| EP-2730572-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | Sunshine Lake Pharma Co., Ltd (CN) | 2014-05-14 | — | — | EP | disclosed |
| WO-2011091446-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011050146-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | HAVCR2, SORD, SLC10A1 | CYP3A4 43/4885CYP2C9 27/4885NR1I2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.